BPA
ALNY icon

Beacon Pointe Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Beacon Pointe Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Sell
1,144
-13
-1% -$3.92K ﹤0.01% 1531
2026
Q1 		$383K Buy
1,157
+367
+46% +$125K ﹤0.01% 1412
2025
Q4 		$314K Sell
790
-164
-17% -$72.6K ﹤0.01% 1245
2025
Q3 		$435K Sell
954
-82
-8% -$33.4K ﹤0.01% 1053
2025
Q2 		$338K Buy
1,036
+169
+19% +$46.8K ﹤0.01% 1001
2025
Q1 		$234K Sell
867
-68
-7% -$17.5K ﹤0.01% 1104
2024
Q4 		$220K Sell
935
-440
-32% -$116K ﹤0.01% 1115
2024
Q3 		$378K Sell
1,375
-137
-9% -$35.7K ﹤0.01% 949
2024
Q2 		$367K Sell
1,512
-124
-8% -$19.6K ﹤0.01% 988
2024
Q1 		$245K Hold
1,636
– – ﹤0.01% 1181
2023
Q4 		$313K Sell
1,636
-55
-3% -$9.37K ﹤0.01% 1065
2023
Q3 		$299K Buy
1,691
+111
+7% +$21.2K ﹤0.01% 1066
2023
Q2 		$300K Sell
1,580
-126
-7% -$25K ﹤0.01% 886
2023
Q1 		$342K Sell
1,706
-84
-5% -$17.7K 0.01% 888
2022
Q4 		$425K Buy
1,790
+33
+2% +$7.04K 0.01% 746
2022
Q3 		$351K Buy
1,757
+156
+10% +$29.8K 0.01% 751
2022
Q2 		$235K Sell
1,601
-139
-8% -$19.7K 0.01% 916
2022
Q1 		$284K Buy
1,740
+395
+29% +$60.2K ﹤0.01% 1001
2021
Q4 		$228K Sell
1,345
-205
-13% -$38.1K 0.01% 831
2021
Q3 		$293K Buy
+1,550
New +$291K 0.01% 716

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Beacon Pointe Advisors's ALNY Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.1% in Q2 2026, selling an estimated $3.92K and leaving 1,144 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

Beacon Pointe Advisors first reported a position in ALNY in Q3 2021 and has held it in 20 quarters since. The position peaked at $435K in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Beacon Pointe Advisors held 1,144 shares of Alnylam Pharmaceuticals worth $344K as of Q2 2026.
  • Beacon Pointe Advisors sold 13 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3.92K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1531 holding.
  • Beacon Pointe Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Beacon Pointe Advisors's Alnylam Pharmaceuticals position peaked at $435K in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.